ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ATOS Atossa Therapeutics Inc

1.61
0.00 (0.00%)
After Hours
Last Updated: 21:00:11
Delayed by 15 minutes
Share Name Share Symbol Market Type
Atossa Therapeutics Inc NASDAQ:ATOS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.61 1.60 1.61 1.66 1.545 1.62 1,037,540 21:00:11

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

11/04/2024 1:30pm

GlobeNewswire Inc.


Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart


From Mar 2024 to May 2024

Click Here for more Atossa Therapeutics Charts.

Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that Chief Executive Officer Steven Quay, M.D., Ph.D., will speak at the Noble Capital Markets Emerging Growth Healthcare Conference on Wednesday, April 17 at 9:00 am ET. The presentation will be available virtually and members of the Company’s leadership team will be available for one-on-one meetings with registered investors of the conference. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Individuals interested in viewing the live presentation can register for the free event here: Noble Healthcare Conference Registration. A video replay of the presentation will be available for 90 days following the event on the investor relations page of Atossa’s website: https://investors.atossatherapeutics.com and on Channelchek: www.channelchek.com. 

About Atossa TherapeuticsAtossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. For more information, please visit www.atossatherapeutics.com.

ContactEric Van ZantenVP, Investor and Public Relations610-529-6219eric.vanzanten@atossainc.com

1 Year Atossa Therapeutics Chart

1 Year Atossa Therapeutics Chart

1 Month Atossa Therapeutics Chart

1 Month Atossa Therapeutics Chart

Your Recent History

Delayed Upgrade Clock